Friday, July 10, 2026

Drug profile · INN

oxaprozin

oxaprozin (DAYPRO) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — oxaprozin
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

oxaprozin (DAYPRO) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN oxaprozin
Brand DAYPRO
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route ORAL
Formulation CAPSULE

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aspirin Cyclooxygenase inhibitor
  2. bromfenac sodium Cyclooxygenase inhibitor
  3. diclofenac potassium Cyclooxygenase inhibitor
  4. diclofenac sodium Cyclooxygenase inhibitor
  5. diflunisal Nervous system (N02)
  6. fenoprofen calcium Cyclooxygenase inhibitor

Frequently asked questions

What is oxaprozin?

oxaprozin (DAYPRO) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for oxaprozin?

DAYPRO is a marketed brand name for oxaprozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of oxaprozin?

oxaprozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.